Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we expect RCKT shares to be under significant pressure today'
Tweet Send to a Friend
Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $42.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
